Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 5/20 | 0.47 |
| ▸ | PLAU | P00749 | 3/20 | 0.47 |
| ▸ | F2 | P00734 | 3/20 | 0.47 |
| ▸ | PLAT | P00750 | 2/20 | 0.47 |
| ▸ | KLKB1 | P03952 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | PLG | P00747 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | TAOK1 | Q7L7X3 | 1/20 | 0.36 |
| ▸ | TAOK3 | Q9H2K8 | 1/20 | 0.36 |
| ▸ | FOLH1 | Q04609 | 4/20 | 0.36 |
| ▸ | F7 | P08709 | 3/20 | 0.36 |
| ▸ | FPR2 | P25090 | 1/20 | 0.36 |
| ▸ | F3 | P13726 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7038403 | 0.92 | FPR2 (0.45) | F10PLAUF2PLATKLKB1 | |
| SCHEMBL7029545 | 0.92 | PLAU (0.44) | F10PLAUF2PLATKLKB1 | |
| SCHEMBL7036018 | 0.91 | F10 (0.42) | F10PLAUF2PLATKLKB1 | |
| SCHEMBL7032270 | 0.90 | PLAU (0.42) | F10PLAUF2PLATKLKB1 | |
| SCHEMBL7029540 | 0.90 | PLAU (0.42) | F10PLAUF2PLATKLKB1 | |
| SCHEMBL7030513 | 0.88 | FPR2 (0.47) | F10PLAUF2PLATKLKB1 | |
| SCHEMBL7032315 | 0.85 | PLAU (0.38) | F10PLAUF2PLATKLKB1 | |
| SCHEMBL7255333 | 0.84 | F10 (0.40) | F10PLAUF2PLATKLKB1 | |
| SCHEMBL7251419 | 0.84 | MEN1 (0.42) | F10PLAUF2PLATKLKB1 | |
| SCHEMBL7034864 | 0.84 | CA2 (0.43) | F10PLAUF2PLATCA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030186967-A1 | Acylresorcinol derivatives are selective vitronectin receptor inhibitors | AMERICAN HOME PRODUCTS CORPORATION (US) | 2003-10-02 | — | — | US | claimed |
| US-20030186967-A1 | Acylresorcinol derivatives are selective vitronectin receptor inhibitors | AMERICAN HOME PRODUCTS CORPORATION (US) | 2003-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030186967-A1 | Acylresorcinol derivatives are selective vitronectin receptor inhibitors | ASGR1, TEK, APLNR | F10 2695/4885PLAU 2202/4885F2 4014/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.